CN106248935B - Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application - Google Patents
Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application Download PDFInfo
- Publication number
- CN106248935B CN106248935B CN201610799439.4A CN201610799439A CN106248935B CN 106248935 B CN106248935 B CN 106248935B CN 201610799439 A CN201610799439 A CN 201610799439A CN 106248935 B CN106248935 B CN 106248935B
- Authority
- CN
- China
- Prior art keywords
- antigen
- mycobacterium tuberculosis
- epitope peptide
- tuberculosis
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to the application of antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide in tuberculosis detection reagent, vaccine and medicine is prepared, the antigen protein Rv1798 and its t cell epitope peptide amino acid sequence are respectively such as SEQ ID NO:Shown in 13.The present invention utilizes mycobacterium tuberculosis Rv1798 proteantigens and its t cell epitope peptide to be used for specific T-cells caused by mycobacterium tuberculosis and B cell immune response as stimulant, the present invention utilizes mycobacterium tuberculosis Rv1798 proteantigens and its epitope peptide to be used for specific T-cells and B cell immune response caused by mycobacterium tuberculosis infection as stimulant, with in the past using comlete antigen compared with, can reduce due to antigen it is impure caused by false positive.The detection reagent prepared by the Rv1798 proteantigens and its epitope peptide can be widely used for the association areas such as auxiliary diagnosis lungy, epidemiological surveillance.Vaccinum Calmette-Guerini and antituberculotic prepared by Rv1798 proteantigens and its epitope peptide can be used for prevention and treatment lungy.
Description
Technical field
The present invention relates to molecular biology and field of immunology, specifically, is related to antigen of mycobacterium tuberculosis albumen
The application of Rv1798 and its t cell epitope peptide in diagnosis reagent, vaccine and medicine preparation.
Background technology
Tuberculosis is the chronic infectious disease as caused by mycobacterium tuberculosis, investigation result show the whole world have three/
One population is in latent infection, and has 5%~10% will likely develop into active tuberculosis in the life in future.From
After the World Health Organization in 1993 announces that tuberculosis turns into global crisis, morbidity and mortality lungy occupy height not always
Under, according to WHO report, newly-increased tuberculosis patient about 8,000,000, there are about 200~3,000,000 people and dies from tuberculosis every year every year.China is 22
The 2nd is occupied in the high burden country of individual tuberculosis, national the 5th epidemiology sampling check result is shown：National 1,300,000 human hairs
Disease, the 14.3% of global incidence is accounted for, China, which is also that 27, whole world resistant tuberculosis is high, bears one of country, multi-drug resistance tuberculosis
Number of patients occupies the whole world first.The active tuberculosis patient of each untreated can infect 10~15 people.Tuberculosis is
Through as the important hygienic issues in the whole world, the great attention of people need to be caused.
The early diagnosis of tuberculosis and prophylactic treatment are most important to control lungy, and clinically conventional is bacteriology side
Method Sputum smears microscopy and Sputum culturing, Sputum smears microscopy be in world wide tuberculosis check in most popular technology, due to
This method simple equipments, it is adapted to use in the area of economics of underdevelopment.But due to requiring high to the bacterial content in sample, therefore should
Method sensitivity is not high, causes largely to apply cloudy patient and is not found so as to turn sun, and applies cloudy patient to have infectiousness, does not allow to neglect
Depending on this method poor sensitivity, is influenceed without species specificity by sputum sample and the state of an illness.Gold of the Sputum culturing as diagnosis of tuberculosis
Standard, but it is long incubation time to be present, having the rapid culture systems such as BACTEC MGIT960 systems now can divide within 2 weeks
From culture mycobacterium tuberculosis, but because the culture medium, nourishing additive agent, miscellaneous bacteria inhibitor of its preparation are expensive, Wu Fa
Developing country is widely popularized, and fast culture pollution rate compared with improvement L-J cultures significantly increases, and causes false positive results
Occur.The conventional detection method for Mass screening is the experiment of cutaneous tuberculosis rhzomorph, uses tulase pure protein to derive
Thing (PPD), due to containing in PPD common to many mycobacterial species (pathogenic mycobacterium, environment mycobacteria and BCG)
Antigen molecule, therefore PPD diagnosis of tuberculosis is specific poor, it is impossible to effectively distinguishes mycobacterium tuberculosis infection and BCG vaccine
Inoculation, imageological examination such as the x-ray inspection of routine, CT examination, MRI inspections, the ultrasonic examination of tuberculosis are expensive, and to body
Body causes necessarily to injure, and specificity is low, is not suitable for conventional inspection diagnosis.
Resided in after mycobacterium tuberculosis intrusion human body in macrophage, immune anti-main to mycobacterium tuberculosis of human body
Should be cellullar immunologic response, the cell being primarily involved in is CD4+ and CD8+T cells.CD8+T cells can pass through perforin, particle
The macrophage infected by mycobacterium tuberculosis or BMDC are killed and remove tuberculosis branch bar so as to reach by the approach such as enzyme
The purpose of bacterium.When the people of infection mycobacterium tuberculosis contacts Specific Antigen of Mycobacterium Tuberculosis again, the production of T lymphopoiesis
Raw IFN-γ, detects that IFN-γ can determine that by monoclonal antibody and once or infects mycobacterium tuberculosis.
The detection method T-SPOT based on T cell is to be captured using IFN-γ specific antibody through tuberculosis antigen at present
Caused IFN-γ after the PBLC culture of stimulation, and showed in a manner of ELISpot develops the color, from
The quantity of spot determines the situation of cell secretion of cytokines, and cellular immune function is evaluated from individual cell level.Using T cell as
The detection of the external interferon on basis is used for auxiliary diagnosis lungy, and the detection method can not only filter out activity knot
Core patient, while incubation period patient can be also detected, it is existing with knot at present so as to preferably prevent and control incubation period tuberculosis
Tuberculosis the specific antigen ESAT-6 and CFP-10 of core Mycobacterium tuberculosis genes group RD1 areas coding holoprotein or polypeptide are stimulant
Commercialization IGRA detection kits, such as QuantiFERON-TB Gold test and T-SPOT, present higher sensitive
Property and specificity.
Rv1798(GI:15608935) it is conservative memebrane protein in Mycobacterium tuberculosis H37Rv ESX excretory systems, contains
610 amino acid, its encoding gene total length 1833bp, can detect in cell conditioned medium, utilize bioinformatics software
Epitope prediction analysis is carried out to it, it is found that Rv1798 albumen has more t cell epitope, there is potential diagnosis to imitate
Energy.
The present invention is established on the basis of reverse vaccinology, and it is possible immune to go out mycobacterium tuberculosis using computational screening
Originality antigenic storehouse, then predict tuberculosis antigen MHC-I class T cell tables using bioinformatics software TE predict and IEDB
Position, synthesizes these polypeptides by solid-state synthetic method, tuberculosis neoantigen is screened first with community immunity screening test, screens
On the one hand Diagnosis of Tuberculosis can be used for by going out Immunodominant Antigenic, on the other hand the transformation available for BCG vaccine.
The content of the invention
It is an object of the invention to provide antigen of mycobacterium tuberculosis albumen Rv1798 application.
It is a further object of the present invention to provide antigen of mycobacterium tuberculosis albumen Rv1798T cell epitope peptides and its application.
The present invention is based on following design：Rv1798 is the conservative memebrane protein on mycobacterium tuberculosis, is that can be cultivated in H37Rv
The secretory protein detected in supernatant.The present invention is based on T cell IFN-γ release tech, utilizes bioinformatics software TE
Predict and IEDB is predicted to T cell antigen epitope on Rv1798 encoding genes, and it is more to synthesize epitope using solid-state synthetic method
Peptide, then the T lymphocyte specific in tuberculosis patient, lung other diseases patient, healthy human body is examined by T-SPOT
Survey, so as to evaluate the sensitivity and specificity that the antigen is used for tuberculosis detection.
In order to realize the object of the invention, the present invention provides antigen of mycobacterium tuberculosis albumen Rv1798 and is preparing tuberculosis detection
With the application in diagnostic reagent；Wherein, the amino acid sequence of the antigen protein Rv1798 such as SEQ ID NO:Shown in 3, or should
Sequence is through replacing, lacking or adding one or several amino acids formed amino with identical immunogenicity and same antigen
Acid sequence.
The present invention also provides antigen of mycobacterium tuberculosis albumen Rv1798T cell epitope peptides, and the epitope peptide is selected from P308
And P309, its amino acid sequence is respectively such as SEQ ID NO:Shown in 1-2.
The present invention also provides epitope peptide or its analog as derived from the t cell epitope peptide.
The present invention also provides the DNA molecular for encoding the epitope peptide.
The present invention also provides expression cassette and expression vector containing the DNA molecular for encoding the epitope peptide.
The present invention also provides the transgenic cell line containing the DNA molecular for encoding the epitope peptide.
The present invention is also provided containing the recombinant bacterium of DNA molecular and its restructuring egg of expression and purification for encoding the epitope peptide
In vain.
The present invention also provides the epitope peptide, DNA molecular, the transgenic cell line or described of the coding epitope peptide
Application of the recombinant protein of recombinant bacterium and its expression and purification in tuberculosis detection reagent, vaccine and medicine is prepared.
The present invention also provides a kind of Diagnosis of Tuberculosis reagent, contains antigen of mycobacterium tuberculosis albumen in the diagnostic reagent
Rv1798, or coding antigen protein Rv1798 DNA molecular, or the weight as caused by the recombinant bacterium containing the DNA molecular
Histone；And/or
The epitope peptide, the DNA molecular of the coding epitope peptide and/or the recombinant protein.
The present invention also provides the tuberculosis T-SPOT detection kits containing above-mentioned diagnostic reagent.The kit also include with
Lower material or reagent：
1. primary antibody：The mouse IgG monoclonal antibody of anti-human or animal's IFN-γ.
2. enzyme marking reagent：Another mouse of anti-human or animal's IFN-γ different epitopes of horseradish peroxidase-labeled
IgG monoclonal antibody.
3. standard items：
Culture plate：The 96 hole micro reaction plates containing pvdf membrane or nitrocellulose filter, contain tuberculosis in Positive control wells
Nonspecific stimulation antigen (such as PHA), negative control hole contain PBS or substrate liquid.
4. reagent and consumptive material needed for other T-SPOT detections.
Preferably, primary antibody is fixed on above-mentioned micro reaction plate.
The present invention is to be based on double-antibody sandwich principle, detects antigen using T-SPOT methods, experimentation is：Wrapped on pvdf membrane
The primary antibody of quilt can combine the IFN-γ in cell conditioned medium as capture antibody, and IFN-γ and can is captured by ELIAS secondary antibody, shown
Color.Two kinds of antibody are the monoclonal antibody of identification IFN-γ difference epitope.
The present invention also provides antigen of mycobacterium tuberculosis albumen Rv1798 and/or the epitope peptide, the coding epitope peptide
DNA molecular, the transgenic cell line or the recombinant protein of the recombinant bacterium and its expression and purification prepare Vaccinum Calmette-Guerini and
Application in antituberculotic.
The present invention also provides a kind of Vaccinum Calmette-Guerini, and its active ingredient is antigen of mycobacterium tuberculosis albumen Rv1798, or compiles
Code antigen protein Rv1798 DNA molecular, or the recombinant protein as caused by the recombinant bacterium containing the DNA molecular；With/
Or,
The epitope peptide, the DNA molecular of the coding epitope peptide and/or the recombinant protein.
The present invention also provides a kind of antituberculotic, and its active ingredient is included with antigen of mycobacterium tuberculosis albumen Rv1798
And/or the epitope peptide is aided with adjuvant immunity experimental animal, the polyclonal antibody of preparation, or divide with tuberculosis as immunogene
Branch bacteroides antigen albumen Rv1798 and/or the epitope peptide are aided with adjuvant immunity experimental animal, using hybridoma as immunogene
Technology and DNA recombinant techniques, the Humanized monoclonal antibodies of the identification epitope peptide antigen of preparation.
The present invention further provides antigen of mycobacterium tuberculosis albumen Rv1798 and/or the epitope peptide and its derivative table
The application of position peptide or its analog in specific T-cells and B cell immune response caused by detection mycobacterium tuberculosis infection.
It is through the epitope peptide and its derivative epitope peptide or its analog antigen or their group by the lymphocyte of human or animal
After compound stimulates, T cell or the cell factor of B cell secretion are detected.
Wherein, the cell factor of tuberculosis specific T-cells secretion includes：Interferon (IFN-γ), interleukin 2
(IL-2), interleukin-4 (IL-4), interleukin 10 (IL-10), tumor necrosis factor α (TNF-α) etc..B cell is secreted
Cell factor include antibody.
Include ELISpot experiment (T- for the detection method of the cell factor of tuberculosis specific T-cells secretion
SPOT), EUSA (ELISA), immune colloid gold experiment, the interior dyeing of cell factor and T cell proliferation test etc..
The detection method of the cell factor of B cell secretion includes EUSA (ELISA) etc..
Peripheral blood of the lymphocyte from human or animal, venous blood, cerebrospinal fluid, pleural effusion or hydrothorax etc..
The present invention has advantages below：
(1) present invention utilizes mycobacterium tuberculosis Rv1798 proteantigens and its t cell epitope peptide to be used for as stimulant
Mycobacterium tuberculosis infection caused by specific T-cells and B cell immune response, with the past using comlete antigen compared with, can
Reduce due to antigen it is impure caused by false positive.
(2) research has shown that, it is immune anti-that epitope provided by the invention can stimulate body to produce stronger T cell
Should, therefore when using above-mentioned epitope to carry out ex vivo T cell interferon release experiment as stimulant, sensitivity significantly carries
It is high.
(3) using the method synthesis epitope polypeptide of synthesis in solid state, quality control is advantageous to, and cost is relatively low, purity is high,
It is adapted to large-scale commercial production.
Embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.Unless otherwise specified, embodiment
In the conventional meanses that are well known to those skilled in the art of used technological means, raw materials used is commercial goods.
The antigen of mycobacterium tuberculosis gene Rv1798 of embodiment 1 clone and the expression and purification of albumen
Rv1798(GI:15608935) be Mycobacterium tuberculosis H37Rv genome encoding conservative memebrane protein, containing 610
Amino acid, its amino acid sequence such as SEQ ID NO:Shown in 3.According to its coding gene sequence, primer is designed, utilizes prokaryotic expression
System (such as Escherichia coli), which is expressed and purified, obtains antigen protein Rv1798.
The synthesis of the antigen of mycobacterium tuberculosis albumen Rv1798T cell epitope peptides of embodiment 2
Based on T cell IFN-γ release tech, Rv1798 is compiled using bioinformatics software TE predict and IEDB
T cell antigen epitope is predicted on code gene, and epitope polypeptide is synthesized using solid-state synthetic method, then by T-SPOT methods to tuberculosis
Patient, lung other diseases patient, the T lymphocyte specific in healthy human body are detected, and are used for so as to evaluate the antigen
The sensitivity and specificity of tuberculosis detection.
The antigen of mycobacterium tuberculosis albumen Rv1798T cell epitope peptides that the present embodiment provides are selected from P308 and P309, its
Amino acid sequence is respectively such as SEQ ID NO:Shown in 1-2.
The preparation of the tuberculosis T-SPOT detection kits of embodiment 3
The kit forms as follows substantially：
1. embodiment 1 prepare proteantigen Rv1798 and/or embodiment it is 2-in-1 into epitope peptide
Antigen：The epitope peptide is selected from least one of P308 and P309.
2. primary antibody：The mouse IgG monoclonal antibody of anti-human or animal's IFN-γ.
Enzyme marking reagent：Another mouse IgG of anti-human or animal's IFN-γ different epitopes of horseradish peroxidase-labeled
Monoclonal antibody.
3. standard items：
Culture plate：The 96 hole micro reaction plates containing pvdf membrane or nitrocellulose filter, contain tuberculosis in Positive control wells
Nonspecific stimulation antigen (such as PHA), negative control hole contain PBS or substrate liquid.
4. reagent and consumptive material needed for other T-SPOT detections.
Primary antibody is fixed on above-mentioned micro reaction plate.
The kit is designed based on double-antibody sandwich principle, detects antigen using T-SPOT methods, experimentation is：
Coated primary antibody can combine the IFN-γ in cell conditioned medium as capture antibody on pvdf membrane, and IFN-γ and can is by enzyme mark two
Anti- capture, colour developing.Two kinds of antibody are the monoclonal antibody of identification IFN-γ difference epitope.
The epitope peptide of embodiment 4 is used for the clinical detection of tuberculosis infection
1. the separation of PBLC
1.1 study subject
1. the screening criteria of volunteer's case：
Clinical manifestation symptom, sign and imaging examination of chest are diagnosed as phthisical, and Sputum culturing is positive lung knot
Core patient.
2. the screening criteria of Pulmonary Disease patients：
Sputum culturing and lung's other diseases that Sputum smears are feminine gender, such as pneumoconiosis, chronic obstructive pulmonary disease Pulmonary Disease patients.
3. the screening criteria of healthy volunteer：
Without tuberculosis clinical symptoms, without tuberculosis patient close contact history, without other diseases or infection.
Selected tuberculosis patient and volunteer's age between 15-80 year, to tuberculosis ward go to a doctor continuous time
Randomly selected in sample.50 tuberculosis volunteers, 40 Pulmonary Disease patients and 55 healthy volunteer's blood are acquired altogether
Sample, peripheric venous blood is gathered using the anticoagulant heparin vacuum blood collection tube of endotoxin-free during blood sampling, every volunteer takes a blood sample about 5ml
~10ml.
1) sample in 4 hours use Ficoll-Hypaque separating liquids separation PBMCs.
2) first by whole blood RPMI-1640 culture mediums 1:1 dilution is mixed, and the separation of certain volume is added in centrifuge tube
Liquid, separating liquid ullage is arrived into the blood sample tiling after dilution, two liquid level interfaces of holding are clear, and separating liquid, anti-freezing are not diluted
Whole blood, the culture volumes of RPMI 1640 are 1:1:1, room temperature (18~26 DEG C), 800g is centrifuged 20 minutes.
3) after centrifugation terminates, ttom of pipe is red blood cell, and intermediate layer is separating liquid, and the superiors are plasma layers, and plasma layer is with separating
It is nebulous mononuclearcell (including the lymphocyte and monocyte) layer of white between liquid layer.White cloud and mist is drawn with suction pipe
Shape cellular layer is simultaneously transferred in 15ml sterile centrifugation tubes, adds the culture mediums of RPMI 1640 to 10ml, at room temperature 10 points of 800g centrifugations
Clock.
4) supernatant discarding, adds the culture mediums of 7ml RPMI 1640 after resuspension, 700g is centrifuged 10 minutes.
5) supernatant discarding adds 0.5ml AIM-V culture mediums that precipitation is resuspended.
6) using automated cell calculating instrument to cell count, with AIM-V culture mediums prepare 500 μ L cell concentrations be 2.5 ×
106/ ml cell suspension.
2. the preparation of epitope peptide
The epitope peptide that solid-phase synthesis in embodiment 2 synthesizes is dissolved with DMSO, each bar epitope peptide is respectively with containing
The RPIM1640 culture mediums of 10% hyclone use after being diluted to finite concentration.
3.T-SPOT detects epitope peptide-specific T-cell
Using the kit of embodiment 3, following reagent is added into the microwell plate of pre-coated primary antibody, each patient sets respectively
4 detection holes：Positive control wells (adding the phytohemagglutinin HA that 100 μ L concentration are 15 μ g/ml as positive stimulus thing), feminine gender
Control wells (adding 100 μ L PBS as negative control), 2 detection holes (are separately added into the final concentration of 20 μ g/ of 100 μ L in each hole
Ml epitope peptide P308, P309), the good PBMC of the 100 above-mentioned dilutions of μ L is added in each hole, makes the quantity of PBMC in every hole up to 25
Ten thousand, antigen and PBMC cells are placed in 37 DEG C, 5%CO2Incubator in cultivate 20 hours.
4. board-washing and result judgement
PBMC cells and antigenic stimulus thing are washed away, adds 100 μ L primary antibodies to be incubated at room temperature 1 hour, is washed 5 times with PBS, add secondary antibody
Incubation at room temperature 1 hour, then washed 5 times with PBS, after adding substrate lucifuge to develop the color 7 minutes, with purified water color development stopping, culture plate is put
The spot number on access panel is dried at ventilating opening.
Result judgement (table 1)：Blank control wells spot number=N, detection hole spot number=T, positive quality control hole spot number=
P。
Table 1T-SPOT result criterions
Two of which epitope peptide detects the result of 50 tuberculosis patients, 40 lung other diseases patients and 55 Healthy Peoples
Statistics is shown in Table 2.
Two epitope peptide detection sensitivities of table 2Rv1798 proteantigens and specificity statistics
| Epitope peptide | Sensitivity (%) | Specificity (%) |
| P308 | 12 | 100 |
| P309 | 18 | 100 |
| Two polypeptide joints | 24 | 100 |
Detection sensitivity=(tuberculosis patient detection number positive/tuberculosis patient sum) × 100%
Detect specificity=1- (consumptive detects number positive+healthy volunteer and detects number positive)/(PUD D
Patient populations+healthy volunteer's sum)
Detect that positive is positive principle according to wall scroll polypeptide, be computed drawing Rv1798 proteantigens P308,
The sensitivity that two epitope peptide joint-detections of P309 go out tuberculosis patient is 24%, specificity 100%.As a result show, tuberculosis
People has immune t-cell immune response to the t cell epitope polypeptide of Rv1798 albumen and its epitope, lung other illness patient and
Healthy People is to its non-responsiveness, it was demonstrated that and Rv1798 albumen and its epitope polypeptide can identify specifically by tuberculosis patient PBMC,
Therefore Rv1798 has the ability of potential diagnosis of tuberculosis, and joint antigen can be used as to be used in diagnosis detection lungy,
Same crowd's screening test also demonstrate that Rv1798 and its epitope polypeptide can stimulate body to produce IFN-γ, and IFN-γ can activate
Macrophage is so as to promote removing of the macrophage to mycobacterium tuberculosis, and it can be considered to by Rv1798 and its epitope polypeptide
Structure and preparation for the vaccine of tuberculosis.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Cause
This, these modifications or improvements, belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. antigen of mycobacterium tuberculosis albumen Rv1798 is preparing tuberculosis detection and the application in diagnostic reagent；Wherein, it is described anti-
Former albumen Rv1798 amino acid sequence such as SEQ ID NO:Shown in 3.
2. antigen of mycobacterium tuberculosis albumen Rv1798 t cell epitope peptides, it is characterised in that the epitope peptide is selected from such as SEQ
ID NO:Amino acid sequence shown in 1 or 2.
3. application of the epitope peptide described in claim 2 in tuberculosis detection reagent is prepared.
4. a kind of Diagnosis of Tuberculosis reagent, it is characterised in that contain antigen of mycobacterium tuberculosis albumen in the diagnostic reagent
Rv1798, or coding antigen protein Rv1798 DNA molecular, or the weight as caused by the recombinant bacterium containing the DNA molecular
Histone；And/or
Epitope peptide described in claim 2, or the DNA molecular of the coding epitope peptide, or by containing the DNA for encoding the epitope peptide
Recombinant protein caused by the recombinant bacterium of molecule.
5. the tuberculosis T-SPOT detection kits containing diagnostic reagent described in claim 4.
6. kit according to claim 5, it is characterised in that contain in the kit：
1. primary antibody：The mouse IgG monoclonal antibody of anti-human or animal's IFN-γ；
2. enzyme marking reagent：Another mouse IgG list of anti-human or animal's IFN-γ different epitopes of horseradish peroxidase-labeled
Clonal antibody；
3. standard items：
Culture plate：The 96 hole micro reaction plates containing pvdf membrane or nitrocellulose filter, contain the non-spy of tuberculosis in Positive control wells
Different in nature stimulator antigen, negative control hole contain PBS；
4. reagent and consumptive material needed for other T-SPOT detections；
Wherein, primary antibody is fixed on above-mentioned micro reaction plate.
7. applications of the antigen of mycobacterium tuberculosis albumen Rv1798 in Vaccinum Calmette-Guerini is prepared, wherein, the antigen protein
Rv1798 amino acid sequence such as SEQ ID NO:Shown in 3.
8. a kind of Vaccinum Calmette-Guerini, it is characterised in that its active ingredient is antigen of mycobacterium tuberculosis albumen Rv1798, or coding institute
State antigen protein Rv1798 DNA molecular, or the recombinant protein as caused by the recombinant bacterium containing the DNA molecular；
Wherein, the amino acid sequence of the antigen protein Rv1798 such as SEQ ID NO:Shown in 3.
9. applications of the antigen of mycobacterium tuberculosis albumen Rv1798 in antituberculotic is prepared, wherein, the antigen protein
Rv1798 amino acid sequence such as SEQ ID NO:Shown in 3.
10. a kind of antituberculotic, it is characterised in that its active ingredient includes making with antigen of mycobacterium tuberculosis albumen Rv1798
For immunogene, it is aided with adjuvant immunity experimental animal, the polyclonal antibody of preparation, or with antigen of mycobacterium tuberculosis albumen
Rv1798 is aided with adjuvant immunity experimental animal, using hybridoma technology or DNA recombinant techniques, the identification of preparation as immunogene
Antigen of mycobacterium tuberculosis albumen Rv1798 Humanized monoclonal antibodies；
Wherein, the amino acid sequence of the antigen protein Rv1798 such as SEQ ID NO:Shown in 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610799439.4A CN106248935B (en) | 2016-08-31 | 2016-08-31 | Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610799439.4A CN106248935B (en) | 2016-08-31 | 2016-08-31 | Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106248935A CN106248935A (en) | 2016-12-21 |
| CN106248935B true CN106248935B (en) | 2018-04-06 |
Family
ID=58080678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610799439.4A Active CN106248935B (en) | 2016-08-31 | 2016-08-31 | Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106248935B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109975543B (en) * | 2019-03-01 | 2022-02-11 | 中国疾病预防控制中心传染病预防控制所 | Application of mycobacterium Ku protein |
| CN117384262B (en) * | 2023-10-18 | 2024-08-06 | 梅州市人民医院(梅州市医学科学院) | Mycobacterium tuberculosis specific T cell HLA-A 0201 restriction epitope peptide pMtb and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101289496A (en) * | 2008-05-30 | 2008-10-22 | 中国医学科学院医学生物学研究所 | Epitope screening method capable of exciting anti-mycobacterium tuberculosis protective immunological reaction of body and uses |
| CN101638430A (en) * | 2009-07-10 | 2010-02-03 | 郑州大学 | Anti-tuberculosis CTL epitope peptide |
| CN101646447A (en) * | 2007-01-19 | 2010-02-10 | 约翰斯霍普金斯大学 | Mycobacterium tuberculosis persistance genes |
| CN103402533A (en) * | 2010-07-23 | 2013-11-20 | 塞尔雷斯蒂斯有限公司 | Use of amino acid sequences from mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom. |
| CN105106971A (en) * | 2007-03-02 | 2015-12-02 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine combination and usage in stimulation immunoreaction |
| CN105481947A (en) * | 2015-12-04 | 2016-04-13 | 南方医科大学 | Mycobacterium tuberculosis specific CD4+T cell epitope peptide P12 and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1117683A2 (en) * | 1998-10-08 | 2001-07-25 | Statens Serum Institut | Tb vaccine and diagnostic based on antigens from the m. tuberculosis cell |
| WO2006029248A2 (en) * | 2004-09-04 | 2006-03-16 | Haper Laboratories Llc | Hollow fiber technique for in vivo study of cell populations |
| RU2014115533A (en) * | 2011-09-23 | 2015-10-27 | Ксир | TUBERCULOSIS DIAGNOSTICS |
-
2016
- 2016-08-31 CN CN201610799439.4A patent/CN106248935B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646447A (en) * | 2007-01-19 | 2010-02-10 | 约翰斯霍普金斯大学 | Mycobacterium tuberculosis persistance genes |
| CN105106971A (en) * | 2007-03-02 | 2015-12-02 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine combination and usage in stimulation immunoreaction |
| CN101289496A (en) * | 2008-05-30 | 2008-10-22 | 中国医学科学院医学生物学研究所 | Epitope screening method capable of exciting anti-mycobacterium tuberculosis protective immunological reaction of body and uses |
| CN101638430A (en) * | 2009-07-10 | 2010-02-03 | 郑州大学 | Anti-tuberculosis CTL epitope peptide |
| CN103402533A (en) * | 2010-07-23 | 2013-11-20 | 塞尔雷斯蒂斯有限公司 | Use of amino acid sequences from mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom. |
| CN105481947A (en) * | 2015-12-04 | 2016-04-13 | 南方医科大学 | Mycobacterium tuberculosis specific CD4+T cell epitope peptide P12 and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria;Louis S. Ates,et al;《PLOS Genetics》;20150504;第11卷(第5期);第1-30页 * |
| NP_216314.1;Lew,J.M.,et al;《NCBI》;20160802;第1-2页 * |
| 结核分枝杆菌VII型分泌系统的研究进展;孙林 等;《中国人兽共患病学报》;20101231;第26卷(第8期);772-775 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106248935A (en) | 2016-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102004155B (en) | Kit and method for detecting mycobacterium tuberculosis infection and application | |
| CN102608333B (en) | Tuberculosis diagnostic composition and application thereof | |
| CN106248934B (en) | Antigen of mycobacterium tuberculosis albumen Rv0446c and its t cell epitope peptide application | |
| WO2016095273A1 (en) | Antigen stimulant for detecting mycobacterium tuberculosis infection, kit, and applications of antigen stimulant | |
| CN106405107B (en) | Antigen of mycobacterium tuberculosis albumen Rv2941 and its t cell epitope peptide application | |
| CN107011418A (en) | Detect antigen polypeptide pond and its application of mycobacterium tuberculosis infection | |
| CN106248935B (en) | Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application | |
| CN106939035B (en) | Mycobacterium tuberculosis T cell epitope polypeptide and application thereof | |
| CN105051537B (en) | Cell-mediated immune response test | |
| CN105601747A (en) | Mycobacterium tuberculosis fusion protein and application thereof in induction of peripheral blood mononuclear cells to generate cytokines | |
| CN105481947A (en) | Mycobacterium tuberculosis specific CD4+T cell epitope peptide P12 and application thereof | |
| CN102212113B (en) | Tuberculosis medicament resistance related tuberculosis-resisting cytotoxic T lymphocyte (CTL) epitope peptide derived from refflux protein and application thereof | |
| CN106226520B (en) | The application of antigen of mycobacterium tuberculosis albumen Rv0865 and its B cell epitope peptide | |
| CN106248936B (en) | The application of antigen of mycobacterium tuberculosis albumen Rv2201 and its t cell epitope peptide | |
| Nagai et al. | Immunological Responses and Epitope Mapping by Tuberculosis‐Associated Antigens within the RD1 Region in Japanese Patients | |
| CN114907460B (en) | Mycobacterium tuberculosis LTBI-RD related protein antigen Th1 epitope peptide and application thereof | |
| CN106442983B (en) | The application of antigen of mycobacterium tuberculosis albumen Rv3793 and its t cell epitope peptide | |
| CN106198971A (en) | The application of antigen of mycobacterium tuberculosis albumen Rv2351c | |
| CN102516356B (en) | Epitope polypeptide applicable to mycobacterium tuberculosis infection detection and application thereof | |
| CN106397553B (en) | The application of antigen of mycobacterium tuberculosis albumen Rv0585c and its t cell epitope peptide | |
| CN114671928A (en) | Application of mycobacterium tuberculosis T cell epitope protein Rv1566c-444 | |
| CN105759054A (en) | ELISPOT detection kit for detecting bovine brucellosis | |
| CN103130873A (en) | Antituberculous CTL (Cytotoxic T Lymphocyte) epitope peptide with drug-resistant related efflux protein source for tuberculosis and application of epitope peptide | |
| Yu et al. | Development of a new cellular immunological detection method for tuberculosis based on HupB protein induced IL-6 release test | |
| CN114736276B (en) | CTL epitope peptide of mycobacterium tuberculosis LTBI-RD related protein antigen and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |